Cinclus Pharma

The ongoing clinical development and testing of linaprazan glurate is showing promising results in acid control and in lowering the Cmax-value.

The company’s research aims to develop an effective treatment for people living with gastroesophageal reflux disease (GERD).

Gastroesophageal reflux disease, or acid reflux, is a condition in which the content of the stomach regurgitates into the esophagus.

Cinclus Pharma’s clinical stage drug candidate, linaprazan glurate, takes a new approach to provide improved management of GERD.

Dr. Prateek Sharma, Medical Advisor and expert in gastrointestinal diseases and cancer, shares his insights on its safety and potential usage areas.

24-hour acid control is the most important characteristic to differentiate an acid-suppressive drug and to create optimal healing conditions.

Significant proportion of severe eGERD patients treated by Gastroenterologists remain unhealed with PPI treatment.

Find links to articles and more where Cinclus Pharma, the Swedish pharma company developing effective treatments for GERD has been mentioned in the press.

Latest interviews and updates from Cinclus Pharma, the Swedish pharma company developing effective treatments for gastric acid related diseases.

Welcome to Cinclus Pharmas' media section. Find the latest interviews and press releases from the Swedish pharma company developing linaprazan glurate.

Cinclus Pharma offers a positive, fast-growing work culture with a skilled and motivated team.

Intervju med Kjell Andersson - medgrundare, Chief Scientific Officer och sedan januari 2026 styrelsemedlem i Cinclus Pharma

Linaprazan, a PCAB drug, regulates stomach acid differently than traditional PPI-based medications by maintaining a normal pH level.

The Board of Directors at Cinclus Pharma has international competence and extensive industry experience in the business and medical fields.

Cinclus Pharma's co-founder and Chairman of the Board, Lennart Hansson, has long experience from leading positions at various pharmaceutical companies.

Cinclus Pharma’s management team has extensive experience in drug discovery.

A clear vision and inspiring mission are key to bringing linaprazan glurate to the global market.

A clear vision and inspiring mission guide the development of linaprazan glurate for the global market.

Cinclus Pharma has an agreement with Zentiva k.s., a leading European pharmaceutical company, for the commercialization and manufacturing of linaprazan glurate, in Europe. The agreement covers all member states in EEA, UK and Switzerland.

Cinclus Pharma, founded by GERD treatment pioneers with Astra and AstraZeneca experience, advances linaprazan glurate.

Contact Cinclus Pharma’s Stockholm, Sweden, headquarters or management team.

Contact Cinclus Pharma’s Stockholm, Sweden, headquarters or board.

A Swedish pharma company bringing relief to the world with the clinical stage drug candidate linaprazan glurate for gastric acid related diseases.

I denna integritetspolicy för Cinclus Pharma Holding AB förklarar vi hur Cinclus Pharma Holding AB, med organisationsnummer (559136-8765), inklusive dotterbolag (”Cinclus Pharma”, ”vi”, ”oss”, ”vår”) samlar in och behandlar dina personuppgifter.